# Syncona Partners LLP

> Syncona Partners LLP is a VC fund in London backing Biotechnology and Medical. See 70 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 70
- Last investment: May 2026
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/syncona-partners-llp/
- Website: https://www.synconaltd.com/

Syncona Partners LLP is a VC fund in London focused on Biotechnology and Medical. Syncona is a leading healthcare company focused on investing in and building global leaders in life science. Their vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.They seek to partner with the best, brightest and most ambitious minds in scienceto build globally competitive businesses. They take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. They focus on delivering dramatic efficacy for patients in areas of high unmet need.Syncona is aligned with two of the premium charitable funders in UK science, The Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders in their business. They make a donation of 0.3% of Net Asset Value to a range of charities each year.

## Contacts

5 contacts available for Syncona Partners LLP. Shizune tracks 10 team members at Syncona Partners LLP. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/syncona-partners-llp?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.8M–$17M |
| Series A | $13M–$110M |
| Series B | $29M–$156M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 19 | 27% |
| Medical | 9 | 13% |
| Health Care | 8 | 11% |
| Therapeutics | 8 | 11% |
| Life Science | 6 | 9% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 17 | 24% |
| Series B | 16 | 23% |
| Seed | 7 | 10% |
| Series C | 6 | 9% |
| Funding Round | 1 | 1% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 18 | 26% |
| United States | 4 | 6% |
| Switzerland | 2 | 3% |
| The Netherlands | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Edward Hodgkin | Partner | 8 | https://shizune.co/investors/profile/edward-hodgkin |
| Magdalena Jonikas | Partner | 4 | https://shizune.co/investors/profile/magdalena-jonikas-90a8 |
| Chris Hollowood | Chief Investment Officer | 9 | https://shizune.co/investors/profile/chris-hollowood |
| Chris Hollowood | Chief Investment Officer | 8 | https://shizune.co/investors/profile/christopher-hollowood |
| Christian Groendahl | Partner | 0 | https://shizune.co/investors/profile/christian-groendahl |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Re-Aim Therapeutics | Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions. | $9.4M | Seed | May 18, 2026 |  |
| Re-Aim Therapeutics | Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions. | $9.4M | Seed | May 18, 2026 |  |
| Apini Therapeutics | Apini is a creating novel small chemical two most prevalent types of inflammatory bowel disease. | $2.4M | Seed | Jun 11, 2025 |  |
| Purespring Therapeutics | Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally. | $104.5M | Series B | Oct 09, 2024 |  |
| Purespring Therapeutics | Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally. | $104.5M | Series B | Oct 09, 2024 |  |
| Resolution Therapeutics | Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases. | $28.9M | Series B | Oct 03, 2024 |  |
| Resolution Therapeutics | Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases. | $28.9M | Series B | Oct 03, 2024 |  |
| Yellowstone Biosciences | Yellowstone seeks to identify a novel class of frequently expressed antigens that can be therapeutically targeted, With the potential to dramatically improve patient outcomes. | $20.9M | Series A | Jun 20, 2024 |  |
| iOnctura | iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M | Series B | Jun 20, 2024 |  |
| Spur Therapeutics | Spur Therapeutics is a clinical-stage biotechnology business dedicated to creating life-changing medicines for crippling chronic illnesses. | $50M | Private Equity | Jun 17, 2024 |  |

10 of 70 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 17 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation) — VC Fund, 16 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-science-enterprises) — VC Fund, 7 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 6 deals together
- [UCL Technology Fund](https://shizune.co/investors/profile/ucl-technology-fund) — VC Fund, 6 deals together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in United Kingdom](https://shizune.co/investors/health-care-vc-funds-united-kingdom)
- [Biotech Investors in United Kingdom](https://shizune.co/investors/biotech-investors-united-kingdom)
- [Biotech VC Funds in United Kingdom](https://shizune.co/investors/biotech-vc-funds-united-kingdom)
- [Health Care Investors in United Kingdom](https://shizune.co/investors/health-care-investors-united-kingdom)
- [Biotechnology VC Funds in Europe](https://shizune.co/investors/biotechnology-vc-funds-europe)
- [Biotech Investors in Europe](https://shizune.co/investors/biotech-investors-europe)

## FAQ

### What does Syncona Partners LLP invest in?

Syncona Partners LLP invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 70 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Syncona Partners LLP's check size?

Syncona Partners LLP typically joins rounds of $1.8M–$17M at Seed, $13M–$110M at Series A and $29M–$156M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Syncona Partners LLP participates in.

### How do I contact Syncona Partners LLP?

Public channels for Syncona Partners LLP include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Syncona Partners LLP?

The team at Syncona Partners LLP includes Edward Hodgkin (Partner), Magdalena Jonikas (Partner) and Chris Hollowood (Chief Investment Officer), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co